We are live on ! Find out more
CC

Commodore Capital Portfolio holdings

AUM $1.73B
1-Year Est. Return 298.96%
This Fund
S&P 500
This Quarter Est. Return
+37.69%
1 Year Est. Return
+298.96%
3 Year Est. Return
+2,048.53%
5 Year Est. Return
+6,668.48%
10 Year Est. Return
–
AUM
$251M
AUM Growth
+$67.1M
Cap. Flow
+$49.6M
Cap. Flow %
19.75%
Top 10 Hldgs %
55.61%
Holding
35
New
7
Increased
11
Reduced
7
Closed
4

Top Buys

Rank Stock Value
1
STSA
Satsuma Pharmaceuticals, Inc. Common Stock
STSA
+$14.7M
2
KURA icon
Kura Oncology
KURA
+$12.3M
3
DYN icon
Dyne Therapeutics
DYN
+$8.32M
4
CBAY
Cymabay Therapeutics
CBAY
+$8.06M
5
KALV
KalVista Pharmaceuticals
KALV
+$5.64M

Top Sells

Rank Stock Value
1
ACRS icon
Aclaris Therapeutics
ACRS
+$6.03M
2
SURF
Surface Oncology, Inc. Common Stock
SURF
+$4.32M
3
FPRX
Five Prime Therapeutics, Inc.
FPRX
+$4.26M
4
IMVT icon
Immunovant
IMVT
+$3.87M
5
XENE icon
Xenon Pharmaceuticals
XENE
+$2.81M

Sector Composition

Rank Sector Weight
1 Healthcare 95.54%
2 Financials 1.05%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
IVA
26
Inventiva
IVA
$1.05B
$3.86M 1.54%
262,658
+31,658
+14% +$485K
VRDN icon
27
Viridian Therapeutics
VRDN
$2.13B
$3.1M 1.24%
+185,781
New +$3.48M
MCRB icon
28
Seres Therapeutics
MCRB
$48M
$2.91M 1.16%
+7,065
New +$3.25M
BLSA
29
DELISTED
BCLS Acquisition Corp. Class A Ordinary Shares
BLSA
$2.64M 1.05%
250,000
– –
MGNX icon
30
MacroGenics
MGNX
$235M
$1.49M 0.59%
+46,630
New +$1.13M
SNCE
31
DELISTED
Science 37 Holdings, Inc. Common Stock
SNCE
$1.01M 0.4%
5,000
– –
BGMS
32
Bio Green Med Solution Inc
BGMS
$5.05M
– –
-74
Closed -$2.07M
IMVT icon
33
Immunovant
IMVT
$8.09B
– –
-83,782
Closed -$3.87M
TPST icon
34
Tempest Therapeutics
TPST
$14.8M
– –
-4,744
Closed -$1.98M
SURF
35
DELISTED
Surface Oncology, Inc. Common Stock
SURF
– –
-467,796
Closed -$4.32M
1
2

Similar funds

RIA
Regal Investment Advisors Kentwood, Michigan $1.73B AUM 17.74% 1-Year Est. Return
PAIM
Punch & Associates Investment Management Edina, Minnesota $1.73B AUM 27.65% 1-Year Est. Return
MCWS
McKinley Carter Wealth Services Wheeling, West Virginia $1.73B AUM 17.28% 1-Year Est. Return
VCA
Verdence Capital Advisors Hunt Valley, Maryland $1.72B AUM 24.88% 1-Year Est. Return
ESBC
E.S. Barr & Co Lexington, Kentucky $1.72B AUM 12.69% 1-Year Est. Return
MSR
Main Street Research Lakeville, Connecticut $1.72B AUM 48.78% 1-Year Est. Return
WJA
Willis Johnson & Associates Houston, Texas $1.72B AUM 16.93% 1-Year Est. Return
OMC
Oasis Management Company Grand Cayman, Cayman Islands $1.72B AUM 32.1% 1-Year Est. Return

Commodore Capital's Q1 2021 Portfolio in Review

As of Q1 2021, Commodore Capital held 35 positions worth $251M, up 36% from $184M the previous quarter. Its ten largest holdings account for 56% of the portfolio.

Commodore Capital deployed $49.6M of net new capital in Q1 2021, opening 7 new positions and adding to 11 existing holdings. Its largest new stake was Satsuma Pharmaceuticals, Inc. Common Stock: 2,431,705 shares worth $14.4M.

By sector, the portfolio is most concentrated in Healthcare at 96% of assets, up from 92% a quarter earlier, followed by Financials.

On the sell side, the largest reduction was Aclaris Therapeutics, an estimated $6.03M trimmed.

  • Commodore Capital's largest Q1 2021 buy was Satsuma Pharmaceuticals, Inc. Common Stock: 2,431,705 shares worth $14.4M.
  • Commodore Capital added most to Kura Oncology in Q1 2021, an estimated $12.3M increase.
  • Commodore Capital's biggest Q1 2021 reduction was Aclaris Therapeutics, cutting an estimated $6.03M.
  • Commodore Capital fully exited Surface Oncology, Inc. Common Stock in Q1 2021, selling an estimated $4.32M.
  • Commodore Capital's ten largest holdings make up 56% of its $251M portfolio in Q1 2021.
  • Commodore Capital opened 7 new positions and closed 4 in Q1 2021.
  • Commodore Capital's portfolio value rose 36% quarter-over-quarter to $251M.

Based on Commodore Capital's 13F filing for Q1 2021, filed 17 May 2021.